Bayer’s Xarelto gets Chinese approval for stroke prevention in patients with non-valvular atrial fibrillation, to treat DVT
Additionally, the CFDA has approved Xarelto for the treatment of deep vein thrombosis (DVT) and for the reduction of the risk of recurrent DVT and pulmonary embolism (PE)